Haematologica (Sep 2019)
Long-term outcome after allogeneic hematopoietic cell transplantation for myelofibrosis
- Marie Robin,
- Liesbeth C. de Wreede,
- Christine Wolschke,
- Johannes Schetelig,
- Diderik-Jan Eikema,
- Maria Teresa Van Lint,
- Nina Simone Knelange,
- Dietrich Beelen,
- Arne Brecht,
- Dietger Niederwieser,
- Antonin Vitek,
- Wolfgang Bethge,
- Renate Arnold,
- Jürgen Finke,
- Liisa Volin,
- Ibrahim Yakoub-Agha,
- Arnon Nagler,
- Xavier Poiré,
- Hermann Einsele,
- Patrice Chevallier,
- Ernst Holler,
- Per Ljungman,
- Stephen Robinson,
- Alekxandar Radujkovic,
- Donal McLornan,
- Yves Chalandon,
- Nicolaus Kröger
Affiliations
- Marie Robin
- Hôpital Saint-Louis, APHP, Université Paris 7, Paris, France
- Liesbeth C. de Wreede
- Department of Biomedical Data Sciences, LUMC, Leiden, the Netherlands and DKMS CTU, Dresden, Germany
- Christine Wolschke
- University Hospital Eppendorf, Hamburg, Germany
- Johannes Schetelig
- Medizinische Klinik und Poliklinik I, Universitätsklinikum Dresden, Dresden, Germany
- Diderik-Jan Eikema
- EBMT Statistical Unit, Leiden, the Netherlands
- Maria Teresa Van Lint
- Ospedale San Martino, Genova, Italy
- Nina Simone Knelange
- EBMT Data Office, Leiden, the Netherlands
- Dietrich Beelen
- University Hospital, Essen, Germany
- Arne Brecht
- Helios HSK Wiesbaden, Wiesbaden, Germany
- Dietger Niederwieser
- University Hospital Leipzig, Leipzig, Germany
- Antonin Vitek
- Institute of Hematology and Blood Transfusion, Prague, Czech Republic
- Wolfgang Bethge
- Universität Tübingen, Tübingen, Germany
- Renate Arnold
- Charité Universitätsmedizin Berlin, Berlin, Germany
- Jürgen Finke
- Division of Medicine I, Hematology, Oncology and Stem Cell Transplantation, University of Freiburg, Freiburg, Germany
- Liisa Volin
- HUCH Comprehensive Cancer Center, Helsinki, Finland
- Ibrahim Yakoub-Agha
- CHU de Lille, INSERM U995, Lille, France
- Arnon Nagler
- Chaim Sheba Medical Center, Tel-Hashomer, Israel
- Xavier Poiré
- Cliniques Universitaires St. Luc, Brussels, Belgium
- Hermann Einsele
- Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany
- Patrice Chevallier
- CHU Nantes, Nantes, France
- Ernst Holler
- University Regensburg, Regensburg, Germany
- Per Ljungman
- Karolinska University Hospital, Stockholm, Sweden
- Stephen Robinson
- Bristol Oncology Centre, Bristol, UK
- Alekxandar Radujkovic
- University of Heidelberg, Heidelberg, Germany
- Donal McLornan
- Comprehensive Cancer Centre, Department of Haematology, Kings College, London, UK
- Yves Chalandon
- Hôpitaux Universitaires de Genève and Faculty of Medicine, University of Geneva, Geneva, Switzerland
- Nicolaus Kröger
- University Hospital Eppendorf, Hamburg, Germany
- DOI
- https://doi.org/10.3324/haematol.2018.205211
- Journal volume & issue
-
Vol. 104,
no. 9
Abstract
Allogeneic hematopoietic stem cell transplant remains the only curative treatment for myelofibrosis. Most post-transplantation events occur during the first two years and hence we aimed to analyze the outcome of 2-year disease-free survivors. A total of 1055 patients with myelofibrosis transplanted between 1995 and 2014 and registered in the registry of the European Society for Blood and Marrow Transplantation were included. Survival was compared to the matched general population to determine excess mortality and the risk factors that are associated. In the 2-year survivors, disease-free survival was 64% (60-68%) and overall survival was 74% (71-78%) at ten years; results were better in younger individuals and in women. Excess mortality was 14% (8-21%) in patients aged
